Logo image
Pharmacological modulation of Sigma1 as a means of regulating cancer cell adaptive immune resistance
Dissertation   Open access

Pharmacological modulation of Sigma1 as a means of regulating cancer cell adaptive immune resistance

Derick Allen Haas
Doctor of Philosophy (Ph.D.), Drexel University
Aug 2020
DOI:
https://doi.org/10.17918/00001393
pdf
Haas_Derick_20207.38 MBDownloadView

Abstract

Interleukin-18 Sigma receptors Immunology Ligands
Adaptive immune resistance in the context of cancer is a process by which cancer cells evade anti-tumor immunity by changing phenotype in response to proinflammatory immune signals, including cytokines such as interferon-gamma. One protein upregulated during this process is Programmed Death Ligand 1 (PD-L1). Cell surface PD-L1 acts as an inhibitory immune checkpoint molecule by binding PD-1 on activated T cells, resulting in suppression of the anti-tumor immune response. PD-L1 can also be incorporated onto cancer cell-derived extracellular vesicles (EVs), which can inactivate T cells both within the tumor microenvironment (TME) and at distant sites. EV cargo proteins have been shown to be important in immune modulation and TME remodeling in cancer. Sigma1 is a unique ligand-regulated integral membrane protein enriched in the endoplasmic reticulum (ER) of cancer cells. Sigma1 acts as a multi-functional scaffolding protein that regulates protein and lipid homeostasis in the secretory pathway of cells. This dissertation examines how Sigma1 can be pharmacologically targeted to suppress both PD-L1 and cancer cell EVs to promote anti-tumor immunity. We found that a selective small molecule Sigma1 inhibitor prevented interferon-gamma induced PD-L1 from progressing through the secretory pathway by blocking its maturation, thus suppressing cell-surface expression and T cell inactivation. The Sigma1 inhibitor also suppressed the production of EVs and the amount of PD-L1 packaged into EVs. By reducing cell surface and EV-associated PD-L1, Sigma1 inhibitors could provide a novel approach to enhancing anti-tumor immunity.

Metrics

24 File views/ downloads
28 Record Views

Details

Logo image